Plain-English translation of NCT07510308 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new vaccine called MSH2-/- tumor cell vaccine for people with advanced colorectal cancer that has stopped responding to standard chemotherapy or targeted drugs. The vaccine is made from your own tumor cells that have been specially modified and inactivated (killed) in the laboratory. Researchers want to see if this treatment is safe, well-tolerated, and whether it can help your immune system fight the cancer.
Many patients with advanced colorectal cancer run out of effective treatment options when standard chemotherapy and targeted therapies stop working. This trial is exploring whether a personalized vaccine approach could offer a new way to help patients whose cancers have become resistant to existing treatments.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive four initial vaccine injections given under the skin over about 9 weeks (three doses given 2 weeks apart, then one dose 4 weeks later), followed by up to eight additional booster doses spaced 4 weeks apart depending on how your cancer responds. You will have regular clinic visits for blood tests, physical exams, and imaging scans to monitor your cancer and check for side effects. The entire active treatment phase could last several months, and you will be followed long-term to track your health and survival.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China